Abatacept, a CTLA4-Ig fusion protein, is approved to treat rheumatoid arthritis and juvenile idiopathic arthritis and has been evaluated in a phase II clinical trial for MS, although failed to show efficacy (63). Here, CTLA4 is linked to juvenile idiopathic arthritis.